TrialBlood2026

Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial.

Jeff P Sharman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.